Cargando…
Biomarkers in individualized management of chimeric antigen receptor T cell therapy
The development of chimeric antigen receptor (CAR) T cell immunotherapy has achieved promising results, both in clinical studies and in commercial products for patients with hematologic malignancies. Despite high remission rates of CAR-T cell therapy in previously untreatable, refractory and/or rela...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216329/ https://www.ncbi.nlm.nih.gov/pubmed/32426136 http://dx.doi.org/10.1186/s40364-020-00190-8 |